Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016

Thompson, Mark G.; Kwong, Jeffrey C.; Regan, Annette K.; Katz, Mark A.; Drews, Steven J.; Azziz‐Baumgartner, Eduardo; Klein, Nicola P.; Chung, Hannah; Effler, Paul V.; Feldman, Becca; Simmonds, Kimberley; Wyant, Brandy E; Dawood, Fatimah S.; Jackson, Michael L.; Fell, Deshayne B.; Levy, Avram; Barda, Noam; Svenson, Lawrence W.; Fink, Rebecca V.; Ball, Sarah; Naleway, Allison L.

doi:10.1093/cid/ciy737

Cited by 146 publications

(91 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[48][49][50][51][52][53] Pregnant women who are immunized against influenza at any time during their pregnancy provide protection to their infants during their first 6 months of life, when they are too young to receive influenza vaccine themselves, through transplacental passage of antibodies. [50][51][52][53][54][55][56][57][58] Infants born to women who receive influenza vaccination during pregnancy can have a risk reduction of up to 72% (95% CI, 39% to 87%) for laboratory-confirmed influenza hospitalization in the first few months of life. 56 It is safe to administer inactivated influenza vaccine to pregnant women during any trimester of gestation and postpartum.…”

Section: Influenza Vaccines During Pregnancy and Breastfeedingmentioning

confidence: 99%

“…[50][51][52][53][54][55][56][57][58] Infants born to women who receive influenza vaccination during pregnancy can have a risk reduction of up to 72% (95% CI, 39% to 87%) for laboratory-confirmed influenza hospitalization in the first few months of life. 56 It is safe to administer inactivated influenza vaccine to pregnant women during any trimester of gestation and postpartum. Any licensed, recommended, and age-appropriate influenza vaccine may be used, although experience with the use of RIV4 in pregnant women is limited.…”

Section: Influenza Vaccines During Pregnancy and Breastfeedingmentioning

confidence: 99%

See 1 more Smart Citation

Recommendations for Prevention and Control of Influenza in Children, 2020–2021

2020

Pediatrics

View full text Add to dashboard Cite

This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2020-2021 season. The American Academy of Pediatrics (AAP) recommends routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Influenza vaccination is an important intervention to protect vulnerable populations and reduce the burden of respiratory illnesses during the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic. Any licensed, recommended, age-appropriate vaccine available can be administered, without preference for one product or formulation over another. Antiviral treatment of influenza with any licensed, recommended, ageappropriate influenza antiviral medication is recommended for children with suspected or confirmed influenza who are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza. Antiviral treatment may be considered for any previously healthy, symptomatic outpatient not at high risk for influenza complications in whom an influenza diagnosis is confirmed or suspected, if treatment can be initiated within 48 hours of illness onset, and for children whose siblings or household contacts either are younger than 6 months or have a high-risk condition that predisposes them to complications of influenza. UPDATES FOR THE 2020-2021 INFLUENZA SEASON 1. The composition of the influenza vaccines for 2020-2021 has been updated. The recommended influenza A(H1N1)pdm09 and A(H3N2) components and the influenza B/Victoria component of the vaccine are new for this season. The B/Yamagata component is unchanged from the previous season. All quadrivalent influenza vaccines include these 4 components. The trivalent vaccines do not include influenza B/Yamagata.

show abstract

Section: Influenza Vaccines During Pregnancy and Breastfeedingmentioning

confidence: 99%

Section: Influenza Vaccines During Pregnancy and Breastfeedingmentioning

confidence: 99%

Recommendations for Prevention and Control of Influenza in Children, 2020–2021

2020

Pediatrics

View full text Add to dashboard Cite

show abstract

“…38,39 Infants born to women who receive influenza vaccination during pregnancy can have a risk reduction of 72% (95% CI, 39% to 87%) for laboratoryconfirmed influenza hospitalization in the first few months of life. 40 It is safe to administer IIV to pregnant women during any trimester of gestation and postpartum. Any licensed, recommended, and ageappropriate influenza vaccine may be used, although experience with the use of RIV4 in pregnant women is limited.…”

Section: Influenza Vaccines During Pregnancy and Breastfeedingmentioning

confidence: 99%

Recommendations for Prevention and Control of Influenza in Children, 2019–2020

Maldonado¹,

Zaoutis²,

Banerjee³

et al. 2019

Pediatrics

View full text Add to dashboard Cite

This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2019-2020 season. The American Academy of Pediatrics continues to recommend routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Any licensed, recommended, age-appropriate vaccine available can be administered, without preference of one product or formulation over another. Antiviral treatment of influenza with any licensed, recommended, age-appropriate influenza antiviral medication continues to be recommended for children with suspected or confirmed influenza, particularly those who are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza. The following updates for the 2019-2020 influenza season are discussed in this document: 1. Both inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) are options for influenza vaccination in children, with no preference. 2. The composition of the influenza vaccines for 2019-2020 has been updated. The A(H1N1)pdm09 and A(H3N2) components of the vaccine are new for this season. The B strains are unchanged from the previous season. 3. All pediatric influenza vaccines will be quadrivalent vaccines. The age indication for some pediatric vaccines has been expanded; therefore, there are now 4 egg-based quadrivalent inactivated influenza vaccines (IIV4s) licensed by the US Food and Drug Administration (FDA) for administration to children 6 months and older, 1 inactivated cell-based quadrivalent inactivated influenza vaccine (cIIV4) for children 4 years and older, and 1 quadrivalent live attenuated influenza vaccine (LAIV4) Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent. The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

show abstract

“…studies also show that vaccination of pregnant women reduces the risk of hospitalisation and influenza complications. research conducted in the years 2010-2016 demonstrated that the application of vaccines reduced the number of hospitalisations; the effect was estimated at 40% (95% Ci: 12-59%) [43]. in addition, maternal vaccination provides protection for babies in the first 6 months of life, as they receive antibodies passing through the placenta whilst they are too small to receive a vaccine [44][45][46].…”

Section: Contraindications and Precautionsmentioning

confidence: 99%

ReCOMmendations for the treatment of INFLUENZA in children for Primary care physiciAnS – COMPAS INFLUENZA

Doniec¹,

Mastalerz-Migas²,

Jackowska³

et al. 2019

fmpcr

View full text Add to dashboard Cite

influenza is an acute infectious disease of the airways that occurs in every age group. the course of the disease may have a different severity and clinical picture, from asymptomatic to severe with symptoms of respiratory failure. the possibilities of pandemic infections and serious complications throughout the course of influenza distinguish it from other viral respiratory diseases, prompting us to treat it in a special way. Diagnosis of the disease is usually clinical in nature, and additional studies may be helpful in clinically relevant cases. the drug recommended for treatment and chemoprophylaxis is oseltamivir. Clinical benefits are greatest if treatment starts as early as possible, within 48 hours of the first symptoms of influenza. Clinical studies indicate that early treatment with oseltamivir may shorten the duration of the disease and reduce the risk of its complications. Annual influenza vaccination is the most effective method of preventing this disease, and the only contraindication to vaccination is the occurrence of an anaphylactic or other severe allergic reaction after a previous vaccination.

show abstract

Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016

Cited by 146 publications

References 43 publications

Recommendations for Prevention and Control of Influenza in Children, 2020–2021

Recommendations for Prevention and Control of Influenza in Children, 2020–2021

Recommendations for Prevention and Control of Influenza in Children, 2019–2020

ReCOMmendations for the treatment of INFLUENZA in children for Primary care physiciAnS – COMPAS INFLUENZA

Contact Info

Product

Resources

About